Evaluating biomarkers in advanced biliary tract cancer treatment with lenvatinib and pembrolizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the clinical efficacy and safety of a combination therapy using lenvatinib and pembrolizumab in patients with advanced biliary tract cancer (BTC). The research focuses on identifying potential predictive biomarkers by analyzing genetic data from blood and tissue samples. By examining real-world clinical outcomes, the study seeks to enhance understanding of treatment responses and improve future therapeutic strategies for BTC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically or cytologically confirmed advanced biliary tract cancer.
* Patients scheduled to receive Lenvatinib + Pembrolizumab for the treatment of advanced biliary tract cancer.
* ECOG performance status of 0-2.
* Patients aged 20 years or older at the time of treatment initiation.
* Patients who understand and consent to participate in this study, and agree to provide samples obtained during the examination process.

Exclusion Criteria:

* Patients who do not consent to participate in the study or withdraw their consent.

Where it's running

• Bundang CHA Medical Center
  Seongnam-si, Gyeonggi-do, South Korea Recruiting

Study contacts

• Principal investigator: Hong Jae Chon, MD. PhD — CHA University
• Study coordinator: Hong Jae Chon, MD. PhD
• Email: minidoctor@cha.ac.kr
• Phone: 82-31-780-3928

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

• Futibatinib and immunotherapy with chemo as first-line treatment for advanced biliary tract cancer

  A first-line treatment test combines Futibatinib with Zimberelimab and Gemcitabine/Cisplatin to see if it improves survival in people with unresectable or advanced biliary tract cancer.

  Recruiting at 4 sites Phase 3 Taiho Pharmaceutical Co., Ltd. · Brisbane and 20 other locations · NCT07710885

• Dual-target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer

  This trial tests a ready-to-use CAR-NK cell therapy that targets HER2 and CEACAM5 in adults with unresectable or metastatic biliary tract cancers after standard therapy to see if it can help control the disease.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07641036

• First-line chemo with hepatic arterial infusion plus Envafolimab and Lenvatinib for unresectable biliary tract cancer

  This trial tests a first-line treatment combining hepatic arterial infusion chemotherapy with Envafolimab and Lenvatinib to see if it helps patients with unresectable biliary tract cancer.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT07636798

• Pembrolizumab and Lenvatinib for recurrent endometrial cancer that has progressed after first-line therapy

  This trial tests a combination of pembrolizumab and lenvatinib to see if it can help adults with recurrent mismatch repair-proficient endometrial cancer after failure of initial platinum-based chemo and immunotherapy.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07594015

• Pembrolizumab plus lenvatinib for vulvar cancer (MITO VULVA-01)

  This trial will test whether combining pembrolizumab with lenvatinib helps people with advanced, recurrent, or unresectable vulvar cancer.

  Recruiting Phase 2 National Cancer Institute, Naples · Naples · NCT07290894

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.